Russell Devore Iii, MD | Authors

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

July 02, 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a

Irinotecan Plus Cisplatin in Patients With Advanced Non- Small-Cell Lung Cancer

August 01, 1998

During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung